Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells

BMC Cancer

Volumn 8, Issue , 2009, Pages

  Guo, Xianling ^a,b   Ma, Nannan ^a   Wang, Jin ^c   Song, Jianrui ^a   Bu, Xinxin ^a   Cheng, Yue ^a   Sun, Kai ^a   Xiong, Haiyan ^a   Jiang, Guocheng ^a   Zhang, Baihe ^a   Wu, Mengchao ^a   Wei, Lixin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Hang Zhou Sanitarium of PLA ^*  (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GLYCOPROTEIN P; LIPOCORTIN 5; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN 1; RNA; TRANSCRIPTION FACTOR AP 1; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING;

EID: 61349152467     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-375     Document Type: Article

References (52)

1. Gottesman MM Fojo T Bates SE Multidrug resistance in cancer: Role of ATP-dependent transporters Nat Rev Cancer 2002, 2(1):48-58 10.1038/ nrc706 11902585
2. Endicott JA Ling V The biochemistry of P-glycoprotein-mediated multidrug resistance Annu Rev Biochem 1989, 58:137-171 10.1146/ annurev.bi.58.070189.001033 2570548
3. Ambudkar SV Dey S Hrycyna CA Ramachandra M Pastan I Gottesman MM Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 1999, 39:361-398 10.1146/ annurev.pharmtox.39.1.361 10331089
4. Hait WN Yang JM Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it Semin Oncol 2005, 32(6 Suppl 7):S16-21 10.1053/ j.seminoncol.2005.09.011 16360718
5. Mickisch G Fajta S Bier H Tschada R Alken P Cross-resistance patterns related to glutathione metabolism in primary human renal cell carcinoma Urol Res 1991, 19(2):99-103 10.1007/BF00368184 1677221
6. Chao CC Cross-resistance to cis-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair Eur J Pharmacol 1996, 305(1-3):213-222 10.1016/0014-2999(96)00168-9 8813556
7. Satta T Isobe K Yamauchi M Nakashima I Takagi H Expression of MDR1 and glutathione S transferase-pi genes and chemosensitivities in human gastrointestinal cancer Cancer 1992, 69(4):941-946 10.1002/ 1097-0142(19920215)69:4<941::AID-CNCR2820690418>3.0.CO;2-H 1735085
8. Kang CD Ahn BK Jeong CS Kim KW Lee HJ Yoo SD Chung BS Kim SH Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein Exp Cell Res 2000, 256(1):300-307 10.1006/excr.2000.4807 10739677
9. Riganti C Miraglia E Viarisio D Costamagna C Pescarmona G Ghigo D Bosia A Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux Cancer Res 2005, 65(2):516-525 15695394
10. Sukhai M Piquette-Miller M Regulation of the multidrug resistance genes by stress signals J Pharm Pharm Sci 2000, 3(2):268-280 10994039
11. Daschner PJ Ciolino HP Plouzek CA Yeh GC Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells Breast Cancer Res Treat 1999, 53(3):229-240 10.1023/A:1006138803392 10369069
12. Whitmarsh AJ Davis RJ Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways J Mol Med 1996, 74(10):589-607 10.1007/s001090050063 8912180
13. Han Z Hong L Han Y Wu K Han S Shen H Li C Yao L Qiao T Fan D Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax J Exp Clin Cancer Res 2007, 26(2):261-268 17725107
14. Chen B Jin F Lu P Lu XL Wang PP Liu YP Yao F Wang SB Effect of mitogen-activated protein kinase signal transduction pathway on multidrug resistance induced by vincristine in gastric cancer cell line MGC803 World J Gastroenterol 2004, 10(6):795-799 15040019
15. Kuo MT Liu Z Wei Y Lin-Lee YC Tatebe S Mills GB Unate H Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling Oncogene 2002, 21(13):1945-1954 10.1038/ sj.onc.1205117 11960367
16. Nwaozuzu OM Sellers LA Barrand MA Signalling pathways influencing basal and H(2)O(2)-induced P-glycoprotein expression in endothelial cells derived from the blood-brain barrier J Neurochem 2003, 87(4):1043-1051 10.1046/j.1471-4159.2003.02061.x 14622133
17. Li J Tang MS Liu B Shi X Huang C A critical role of PI-3K/Akt/JNKs pathway in benzo[a]pyrene diol-epoxide (B[a]PDE)-induced AP-1 transactivation in mouse epidermal Cl41 cells Oncogene 2004, 23(22):3932-3944 10.1038/sj.onc.1207501 15021902
18. Huang C Ma WY Maxiner A Sun Y Dong Z p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389 J Biol Chem 1999, 274(18):12229-12235 10.1074/jbc.274.18.12229 10212189
19. Mantwill K Kohler-Vargas N Bernshausen A Bieler A Lage H Kaszubiak A Surowiak P Dravits T Treiber U Hartung R et al Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: Implications for combinatorial treatment regimen with chemotherapeutic agents Cancer Res 2006, 66(14):7195-7202 10.1158/ 0008-5472.CAN-05-2339 16849566
20. Davies MP O'Neill PA Innes H Sibson DR Prime W Holcombe C Foster CS Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer J Mol Endocrinol 2004, 33(3):773-782 10.1677/jme.1.01574 15591034
21. Zhao Y You H Liu F An H Shi Y Yu Q Fan D Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells Cancer Lett 2002, 185(2):211-218 10.1016/ S0304-3835(02)00264-1 12169395
22. Ling V Multidrug resistance: Molecular mechanisms and clinical relevance Cancer Chemother Pharmacol 1997, 40(Suppl):S3-8 10.1007/s002800051053 9272126
23. Ohga T Koike K Ono M Makino Y Itagaki Y Tanimoto M Kuwano M Kohno K Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light Cancer Res 1996, 56(18):4224-4228 8797596
24. Cornwell MM Smith DE SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity J Biol Chem 1993, 268(26):19505-19511 8103518
25. Chin KV Ueda K Pastan I Gottesman MM Modulation of activity of the promoter of the human MDR1 gene by Ras and p53 Science 1992, 255(5043):459-462 10.1126/science.1346476 1346476
26. Glazer RI Rohlff C Transcriptional regulation of multidrug resistance in breast cancer Breast Cancer Res Treat 1994, 31(2-3):263-271 10.1007/ BF00666159 7881104
27. Eferl R Wagner EF AP-1: A double-edged sword in tumorigenesis Nat Rev Cancer 2003, 3(11):859-868 10.1038/nrc1209 14668816
28. Hayakawa J Depatie C Ohmichi M Mercola D The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair J Biol Chem 2003, 278(23):20582-20592 10.1074/ jbc.M210992200 12663670
29. Wu Y Hiwasa T Isogai E Sonoda T Kita K Chen Z Sugaya S Yamamori H Tanzawa H Suzuki N Activation of MAP kinases by 5-fluorouracil in a 5-fluorouracil-resistant variant human cell line derived from a KT breast cancer cell line Int J Oncol 1998, 13(6):1241-1245 9824638
30. Mistry P Stewart AJ Dangerfield W Okiji S Liddle C Bootle D Plumb JA Templeton D Charlton P In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576 Cancer Res 2001, 61(2):749-758 11212278
31. Pan B Yao KS Monia BP Dean NM McKay RA Hamilton TC O'Dwyer PJ Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): Evidence for the role of transcription factor overexpression in determining resistant phenotype Biochem Pharmacol 2002, 63(9):1699-1707 10.1016/S0006-2952(02)00841-9 12007573
32. Wendling J Marchand A Mauviel A Verrecchia F 5-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/ activator protein-1 activation Mol Pharmacol 2003, 64(3):707-713 10.1124/ mol.64.3.707 12920208
33. Gottesman MM Fojo T Bates SE Multidrug resistance in cancer: Role of ATP-dependent transporters Nat Rev Cancer 2002, 2(1):48-58 10.1038/ nrc706 11902585
34. Simon SM Schindler M Cell biological mechanisms of multidrug resistance in tumors Proc Natl Acad Sci USA 1994, 91(9):3497-3504 43607 7909602 10.1073/pnas.91.9.3497
35. Choi JH Lim HY Joo HJ Kim HS Yi JW Kim HC Cho YK Kim MW Lee KB Expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection Br J Cancer 2002, 86(10):1578-1585 10.1038/ sj.bjc.6600305 12085207
36. Lacueva FJ Teruel A Calpena R Medrano J Mayol MJ Perez-Vazquez MT Rufete C Camarasa MV Ferragut JA Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies Histopathology 1998, 32(4):328-334 10.1046/ j.1365-2559.1998.00381.x 9602329
37. Li L Jiang AC Dong P Wan Y Yu ZW The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol Otolaryngol Head Neck Surg 2007, 137(4):659-664 10.1016/j.otohns.2007.04.026 17903587
38. Ueda K Pastan I Gottesman MM Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene J Biol Chem 1987, 262(36):17432-17436 2891692
39. Chen TK Smith LM Gebhardt DK Birrer MJ Brown PH Activation and inhibition of the AP-1 complex in human breast cancer cells Mol Carcinog 1996, 15(3):215-226 10.1002/ (SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G 8597534
40. Rohlff C Safa B Rahman A Cho-Chung YS Klecker RW Glazer RI Reversal of resistance to adriamycin by 8-chloro-cyclic AMP in adriamycin-resistant HL-60 leukemia cells is associated with reduction of type I cyclic AMP-dependent protein kinase and cyclic AMP response element-binding protein DNA-binding activities Mol Pharmacol 1993, 43(3):372-379 8383802
41. Johnstone RW Ruefli AA Lowe SW Apoptosis: A link between cancer genetics and chemotherapy Cell 2002, 108(2):153-164 10.1016/S0092-8674(02)00625-6 11832206
42. Barancik M Bohacova V Kvackajova J Hudecova S Krizanova O Breier A SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance Eur J Pharm Sci 2001, 14(1):29-36 10.1016/S0928-0987(01)00139-7 11457647
43. Kisucka J Barancik M Bohacova V Breier A Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells Gen Physiol Biophys 2001, 20(4):439-444 11989653
44. Losa JH Parada Cobo C Viniegra JG Sanchez-Arevalo Lobo VJ Ramon y Cajal S Sanchez-Prieto R Role of the p38 MAPK pathway in cisplatin-based therapy Oncogene 2003, 22(26):3998-4006 10.1038/sj.onc.1206608 12821934
45. Hazzalin CA Cano E Cuenda A Barratt MJ Cohen P Mahadevan LC p38/RK is essential for stress-induced nuclear responses: JNK/SAPKs and c-Jun/ ATF-2 phosphorylation are insufficient Curr Biol 1996, 6(8):1028-1031 10.1016/S0960-9822(02)00649-8 8805335
46. Han TH Prywes R Regulatory role of MEF2D in serum induction of the c-jun promoter Mol Cell Biol 1995, 15(6):2907-2915 230521 7760790
47. Han J Jiang Y Li Z Kravchenko VV Ulevitch RJ Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation Nature 1997, 386(6622):296-299 10.1038/386296a0 9069290
48. Katayama K Yoshioka S Tsukahara S Mitsuhashi J Sugimoto Y Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein Mol Cancer Ther 2007, 6(7):2092-2102 10.1158/1535-7163.MCT-07-0148 17620438
49. Osborn MT Berry A Ruberu MS Ning B Bell LM Chambers TC Phorbol ester induced MDR1 expression in K562 cells occurs independently of mitogen-activated protein kinase signaling pathways Oncogene 1999, 18(42):5756-5764 10.1038/sj.onc.1202943 10523856
50. Assefa Z Vantieghem A Declercq W Vandenabeele P Vandenheede JR Merlevede W de Witte P Agostinis P The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin J Biol Chem 1999, 274(13):8788-8796 10.1074/jbc.274.13.8788 10085120
51. Yang JM Vassil A Hait WN Involvement of phosphatidylinositol-3-kinase in membrane ruffling induced by P-glycoprotein substrates in multidrug-resistant carcinoma cells Biochem Pharmacol 2002, 63(5):959-966 10.1016/S0006-2952(02)00838-9 11911848
52. Barancik M Bohacova V Sedlak J Sulova Z Breier A LY294002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance Eur J Pharm Sci 2006, 29(5):426-434 10.1016/j.ejps.2006.08.006 17010577